487 related articles for article (PubMed ID: 32786022)
1. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
[TBL] [Abstract][Full Text] [Related]
2. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
Tsung I; Worden FP; Fontana RJ
Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143
[TBL] [Abstract][Full Text] [Related]
3. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
4. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
6. Tri-Site Academic Center Experience with Immunotherapy for Metastatic Skin Cancer in Solid Organ Transplant Patients.
Berman HS; Degesys CA; Tolaymat L
South Med J; 2023 Feb; 116(2):220-224. PubMed ID: 36724539
[TBL] [Abstract][Full Text] [Related]
7. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort.
Remon J; Auclin E; Zubiri L; Schneider S; Rodriguez-Abreu D; Minatta N; Gautschi O; Aboubakar F; Muñoz-Couselo E; Pierret T; Rothschild SI; Cortiula F; Reynolds KL; Thibault C; Gavralidis A; Blais N; Barlesi F; Planchard D; Besse BMD
ESMO Open; 2024 May; 9(5):103004. PubMed ID: 38653155
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.
Abdel-Wahab N; Safa H; Abudayyeh A; Johnson DH; Trinh VA; Zobniw CM; Lin H; Wong MK; Abdelrahim M; Gaber AO; Suarez-Almazor ME; Diab A
J Immunother Cancer; 2019 Apr; 7(1):106. PubMed ID: 30992053
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.
Fisher J; Zeitouni N; Fan W; Samie FH
J Am Acad Dermatol; 2020 Jun; 82(6):1490-1500. PubMed ID: 31302190
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management.
Ferrándiz-Pulido C; Leiter U; Harwood C; Proby CM; Guthoff M; Scheel CH; Westhoff TH; Bouwes Bavinck JN; Meyer T; Nägeli MC; Del Marmol V; Lebbé C; Geusau A
Transplantation; 2023 Jul; 107(7):1452-1462. PubMed ID: 36706163
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS; Oldham H; Cetnar J; Taylor M
J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
[TBL] [Abstract][Full Text] [Related]
13. Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
Nguyen LS; Ortuno S; Lebrun-Vignes B; Johnson DB; Moslehi JJ; Hertig A; Salem JE
Eur J Cancer; 2021 May; 148():36-47. PubMed ID: 33721705
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
15. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
16. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.
Murakami N; Mulvaney P; Danesh M; Abudayyeh A; Diab A; Abdel-Wahab N; Abdelrahim M; Khairallah P; Shirazian S; Kukla A; Owoyemi IO; Alhamad T; Husami S; Menon M; Santeusanio A; Blosser CD; Zuniga SC; Soler MJ; Moreso F; Mithani Z; Ortiz-Melo D; Jaimes EA; Gutgarts V; Lum E; Danovitch GM; Cardarelli F; Drews RE; Bassil C; Swank JL; Westphal S; Mannon RB; Shirai K; Kitchlu A; Ong S; Machado SM; Mothi SS; Ott PA; Rahma O; Hodi FS; Sise ME; Gupta S; Leaf DE; Devoe CE; Wanchoo R; Nair VV; Schmults CD; Hanna GJ; Sprangers B; Riella LV; Jhaveri KD;
Kidney Int; 2021 Jul; 100(1):196-205. PubMed ID: 33359528
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
19. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
20. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]